⚠️ Mechanism
Ginkgo is a weak inhibitor of CYP3A4, which decreases metabolism of CYP3A4 substrates, potentially increasing their plasma concentrations and risk of adverse effects.
📋 Effect
Increased plasma levels of montelukast (leukotriene-antagonists), potentially leading to toxicity or enhanced adverse effects.
💊 Management
Monitor for increased adverse effects of montelukast. Dose reduction may be necessary. Consider alternative supplement or consult healthcare provider.
Plain Language Summary
This combination carries a moderate risk because Ginkgo can prevent your body from breaking down the medication properly. This may lead to higher levels of the drug in your blood, which could increase your risk of experiencing side effects.
Source
Flockhart CYP450 Table (drug-interactions.medicine.iu.edu)
Supporting Research
Ginkgo biloba for cognitive impairment and dementia
Ginkgo biloba for cognitive impairment and dementia
Ginkgo biloba for tinnitus
Ginkgo biloba for tinnitus
Ginkgo biloba for intermittent claudication
The Comparative Efficacy of Multiple Interventions for Mild Cognitive Impairment in Alzheimer's Disease: A Bayesian Network Meta-Analysis
Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-analysis
Ginkgo biloba for intermittent claudication
Medical Disclaimer: This interaction record is for informational and educational purposes only and does not constitute medical advice. Drug-supplement interactions can be dangerous. Always consult your healthcare provider or pharmacist before combining any supplement with prescription medications. Do not stop or change any medication without professional guidance.